 |
|
 |
 |

Home > Company Index > Drugs > Biotechnology-Medicine > Xcyte Therapies, Inc.
 |
Xcyte Therapies, Inc. |
 |
 |
 |
PROFILE |
 |
Xcyte Therapies is issuing a T-cell call to arms. The development-stage company is working on therapy technology, called Xcellerate, to spur the immune system into action. Drawing disease-fighting T-cells from the patient's blood, the Xcellerate system activates the cells outside the body and re-injects them intravenously; the T-cells may then be used to treat diseases such as HIV and cancer and support immune systems weakened by chemotherapy, post-transplant suppression therapies, congenital disorders, and age. The therapy can be performed on an outpatient basis in 30 minutes and could be used in conjunction with other therapies, thanks to its low toxicity. CEO Ronald Berenson founded the firm in 1996.
COMPETITION |
 |
AVANT Immunotherapeutics, Inc. (AVAN)
Alexion Pharmaceuticals, Inc. (ALXN)
CEL-SCI Corporation (CVM)
|
 |
FINANCIAL OVERVIEW |
 |
Fiscal Year-End: December
1999 Sales (mil.): 0.00
Employees: 64
Revenue per employee: $0.00
KEY PEOPLE |
 |
Ronald J. Berenson
CEO
Kathi L. Cordova
CFO
CONTACT INFO |
 |
1124 Columbia St., Ste. 130
Seattle, WA 98104
US
Phone: 206-262-6200
Fax: 206-262-0900
Online: Web Site
|
 |
 |
 |
|
Hoover's Company Capsule
Copyright © 2001, Hoover's Inc. Austin, Texas.
For changes and updates, contact Hoover's directly.
|

|
 |
 |
|
 |